Development of animal models against emerging coronaviruses: From SARS to MERS coronavirus

Virology

Volumn 479-480, Issue , 2015, Pages 247-258

  Sutton, Troy C ^a   Subbarao, Kanta ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Animal models; Coronaviruses; MERS CoV; Receptor; SARS CoV

Indexed keywords

ANIMAL; COMMUNICABLE DISEASE; CORONAVIRUS INFECTION; DISEASE MODEL; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; HOST RANGE; HUMAN; ISOLATION AND PURIFICATION; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PATHOGENICITY; PHYSIOLOGY; SARS CORONAVIRUS; VIROLOGY;

ANIMALS; COMMUNICABLE DISEASES, EMERGING; CORONAVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; HOST SPECIFICITY; HOST-PATHOGEN INTERACTIONS; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; SARS VIRUS;

EID: 84937511375     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2015.02.030     Document Type: Review

References (114)

1. Adney R.R., van Doremalen N., VBrown V.R., Bushmater T., Scott D., de Wit E., et al. Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels. Emerg. Infect. Dis. 2014, 20(12):1999-2005.
2. Al-Tawfiq J.A., Memish Z.A. Middle East respiratory syndrome coronavirus: epidemiology and disease control measures. Infect. Drug Resist. 2014, 7:281-287.
3. Alagaili A.N., Briese T., Mishra N., Kapoor V., Sameroff S.C., Burbelo P.D., et al. Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. mBio 2014, 5(2):e00884-14.
4. Azhar E.I., El-Kafrawy S.A., Farraj S.A., Hassan A.M., Al-Saeed M.S., Hashem A.M., et al. Evidence for camel-to-human transmission of MERS coronavirus. N. Engl. J. Med. 2014, 370(26):2499-2505.
5. Barlan A., Zhao J., Sarkar M.K., Li K., McCray P.B., Perlman S., et al. Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection. J. Virol. 2014, 88(9):4953-4961.
6. Bermingham A., Chand M.A., Brown C.S., Aarons E., Tong C., Langrish C., et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Eurosurveillance 2012, 17(40):20290.
7. Bisht H., Roberts A., Vogel L., Bukreyev A., Collins P.L., Murphy B.R., et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl. Acad. Sci. USA 2004, 101(17):6641-6646.
8. Booth C.M., Matukas L.M., Tomlinson G.A., Rachlis A.R., Rose D.B., Dwosh H.A., et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. J. Am. Med. Assoc. 2003, 289(21):2801-2809.
9. Buchholz U.J., Bukreyev A., Yang L., Lamirande E.W., Murphy B.R., Subbarao K., et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl. Acad. Sci. USA 2004, 101(26):9804-9809.
10. Chan J.F., Chan K.H., Kao R.Y., To K.K., Zheng B.J., Li C.P., et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J. Infect. 2013, 67(6):606-616.
11. Chan J.W., Ng C.K., Chan Y.H., Mok T.Y., Lee S., Chu S.Y., et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax 2003, 58(8):686-689.
12. Chinese SMEC Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science 2004, 303(5664):1666-1669.
13. Chu Y.K., Ali G.D., Jia F., Li Q., Kelvin D., Couch R.C., et al. The SARS-CoV ferret model in an infection-challenge study. Virology 2008, 374(1):151-163.
14. Cockrell A.S., Peck K.M., Yount B.L., Agnihothram S.S., Scobey T., Curnes N.R., et al. Mouse dipeptidyl peptidase 4 is not a functional receptor for Middle East respiratory syndrome coronavirus infection. J. Virol. 2014, 88(9):5195-5199.
15. Coleman C.M., Matthews K.L., Goicochea L., Frieman M.B. Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. J. Gen. Virol. 2014, 95(Pt 2):408-412.
16. Coleman C.M., Liu Y.V., Mu H., Taylor J.K., Massare M., Flyer D.C., et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 2014, 32(26):3169-3174.
17. Darnell M.E., Plant E.P., Watanabe H., Byrum R., Claire M., Ward J.M., et al. Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets. J. Infect. Dis. 2007, 196(9):1329-1338.
18. Day C.W., Baric R., Cai S.X., Frieman M., Kumaki Y., Morrey J.D., et al. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology 2009, 395(2):210-222.
19. de Wilde A.H., Jochmans D., Posthuma C.C., Zevenhoven-Dobbe J.C., van Nieuwkoop S., Bestebroer T.M., et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob. Agents Chemother. 2014, 58(8):4875-4884.
20. de Wit E., Rasmussen A.L., Falzarano D., Bushmaker T., Feldmann F., Brining D.L., et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc. Natl. Acad. Sci. USA 2013, 110(41):16598-16603.
21. de Wit E., Prescott J., Baseler L., Bushmaker T., Thomas T., Lackemeyer M.G., et al. The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PloS One 2013, 8(7):e69127.
22. Ding Y., Wang H., Shen H., Li Z., Geng J., Han H., et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J. Pathol. 2003, 200(3):282-289.
23. Donnelly C.A., Ghani A.C., Leung G.M., Hedley A.J., Fraser C., Riley S., et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 2003, 361(9371):1761-1766.
24. Doudna J.A., Charpentier E. Genome editing. the new frontier of genome engineering with CRISPR-Cas9. Science 2014, 346(6213):1258096.
25. Dyall J., Coleman C.M., Hart B.J., Venkataraman T., Holbrook M.R., Kindrachuk J., et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob. Agents Chemother. 2014, 58(8):4885-4893.
26. ECDC, 2014. Communicable Disease Threats Report Week 50, European Centre for Disease Prevention and Control, Sweden [cited 2014 December 14, 2014]. Available from: . http://ecdc.europa.eu/en/publications/Publications/communicable-disease-threats-report-13-dec-2014.pdf.
27. FDA, 2014. Guidance for industry product development under the animal rule. In: US Department of Health and Human Services (May 2014 ed.), Food and Drug Administration (FDA); Silver Spring, MD.
28. Falzarano D., de Wit E., Rasmussen A.L., Feldmann F., Okumura A., Scott D.P., et al. Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat. Med. 2013, 19(10):1313-1317.
29. Falzarano D., de Wit E., Feldmann F., Rasmussen A.L., Okumura A., Peng X., et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog. 2014, 10(8):e1004250.
30. Fouchier R.A., Kuiken T., Schutten M., van Amerongen G., van Doornum G.J., van den Hoogen B.G., et al. Aetiology: Koch[U+05F3]s postulates fulfilled for SARS virus. Nature 2003, 423(6937):240.
31. Franks T.J., Chong P.Y., Chui P., Galvin J.R., Lourens R.M., Reid A.H., et al. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. Hum. Pathol. 2003, 34(8):743-748.
32. Frieman M., Yount B., Agnihothram S., Page C., Donaldson E., Roberts A., et al. Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease. J. Virol. 2012, 86(2):884-897.
33. Frieman M.B., Chen J., Morrison T.E., Whitmore A., Funkhouser W., Ward J.M., et al. SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. PLoS Pathog. 2010, 6(4):e1000849.
34. Ge X.Y., Li J.L., Yang X.L., Chmura A.A., Zhu G., Epstein J.H., et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 2013, 503(7477):535-538.
35. Glass W.G., Subbarao K., Murphy B., Murphy P.M. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J. Immunol. 2004, 173(6):4030-4039.
36. Graham R.L., Donaldson E.F., Baric R.S. A decade after SARS: strategies for controlling emerging coronaviruses. Nat. Rev. Microbiol. 2013, 11(12):836-848.
37. Greenough T.C., Carville A., Coderre J., Somasundaran M., Sullivan J.L., Luzuriaga K., et al. Pneumonitis and multi-organ system disease in common marmosets (Callithrix jacchus) infected with the severe acute respiratory syndrome-associated coronavirus. Am. J. Pathol. 2005, 167(2):455-463.
38. Haagmans B.L., Al Dhahiry S.H., Reusken C.B., Raj V.S., Galiano M., Myers R., et al. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect. Dis. 2014, 14(2):140-145.
39. Hart B.J., Dyall J., Postnikova E., Zhou H., Kindrachuk J., Johnson R.F., et al. Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J. Gen. Virol. 2014, 95(Pt 3):571-577.
40. Hemida M.G., Perera R.A., Wang P., Alhammadi M.A., Siu L.Y., Li M., et al. Middle East respiratory syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to 2013. Eurosurveillance 2013, 18(50):20659.
41. Hilgenfeld R., Peiris M. From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. Antivir. Res. 2013, 100(1):286-295.
42. Hogan R.J., Gao G., Rowe T., Bell P., Flieder D., Paragas J., et al. Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1. J. Virol. 2004, 78(20):11416-11421.
43. Jeffers S.A., Tusell S.M., Gillim-Ross L., Hemmila E.M., Achenbach J.E., Babcock G.J., et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. USA 2004, 101(44):15748-15753.
44. Karlberg J., Chong D.S., Lai W.Y. Do men have a higher case fatality rate of severe acute respiratory syndrome than women do?. Am. J. Epidemiol. 2004, 159(3):229-231.
45. Kim E., Okada K., Kenniston T., Raj V.S., AlHajri M.M., Farag E.A., et al. Immunogenicity of an adenoviral-based Middle East respiratory syndrome coronavirus vaccine in BALB/c mice. Vaccine 2014, 32(45):5975-5982.
46. Kobinger G.P., Figueredo J.M., Rowe T., Zhi Y., Gao G., Sanmiguel J.C., et al. Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques. Vaccine 2007, 25(28):5220-5231.
47. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003, 348(20):1953-1966.
48. Kuiken T., Fouchier R.A., Schutten M., Rimmelzwaan G.F., van Amerongen G., van Riel D., et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003, 362(9380):263-270.
49. Lamirande E.W., DeDiego M.L., Roberts A., Jackson J.P., Alvarez E., Sheahan T., et al. A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters. J. Virol. 2008, 82(15):7721-7724.
50. Lau S.K., Woo P.C., Li K.S., Huang Y., Tsoi H.W., Wong B.H., et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl. Acad. Sci. USA 2005, 102(39):14040-14045.
51. Lawler J.V., Endy T.P., Hensley L.E., Garrison A., Fritz E.A., Lesar M., et al. Cynomolgus macaque as an animal model for severe acute respiratory syndrome. PLoS Med. 2006, 3(5):e149.
52. Li F. Structural analysis of major species barriers between humans and palm civets for severe acute respiratory syndrome coronavirus infections. J. Virol. 2008, 82(14):6984-6991.
53. Li F., Li W., Farzan M., Harrison S.C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 2005, 309(5742):1864-1868.
54. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426(6965):450-454.
55. Li W., Greenough T.C., Moore M.J., Vasilieva N., Somasundaran M., Sullivan J.L., et al. Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2. J. Virol. 2004, 78(20):11429-11433.
56. Li W., Zhang C., Sui J., Kuhn J.H., Moore M.J., Luo S., et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 2005, 24(8):1634-1643.
57. Liang G., Chen Q., Xu J., Liu Y., Lim W., Peiris J.S., et al. Laboratory diagnosis of four recent sporadic cases of community-acquired SARS, Guangdong Province, China. Emerg. Infect. Dis. 2004, 10(10):1774-1781.
58. Liang L., He C., Lei M., Li S., Hao Y., Zhu H., et al. Pathology of guinea pigs experimentally infected with a novel reovirus and coronavirus isolated from SARS patients. DNA Cell Biol. 2005, 24(8):485-490.
59. Lu G., Hu Y., Wang Q., Qi J., Gao F., Li Y., et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013, 500(7461):227-231.
60. Martina B.E., Haagmans B.L., Kuiken T., Fouchier R.A., Rimmelzwaan G.F., Van Amerongen G., et al. Virology: SARS virus infection of cats and ferrets. Nature 2003, 425(6961):915.
61. Masters P.S., Perlman S. Coronaviruses. Fields Virology 2013, 6:825-858. Lippincott Williams, Philadelphia.
62. McAuliffe J., Vogel L., Roberts A., Fahle G., Fischer S., Shieh W.J., et al. Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. Virology 2004, 330(1):8-15.
63. McCray P.B., Pewe L., Wohlford-Lenane C., Hickey M., Manzel L., Shi L., et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 2007, 81(2):813-821.
64. Memish Z.A., Cotten M., Meyer B., Watson S.J., Alsahafi A.J., Al Rabeeah A.A., et al. Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013. Emerg. Infect. Dis. 2014, 20(6):1012-1015.
65. Meyer B., Muller M.A., Corman V.M., Reusken C.B., Ritz D., Godeke G.J., et al. Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013. Emerg. Infect. Dis. 2014, 20(4):552-559.
66. Munster V.J., de Wit E., Feldmann H. Pneumonia from human coronavirus in a macaque model. N. Engl. J. Med. 2013, 368(16):1560-1562.
67. Netland J., Meyerholz D.K., Moore S., Cassell M., Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J. Virol. 2008, 82(15):7264-7275.
68. Nicholls J.M., Poon L.L., Lee K.C., Ng W.F., Lai S.T., Leung C.Y., et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003, 361(9371):1773-1778.
69. Normile D. Infectious diseases. Second lab accident fuels fears about SARS. Science 2004, 303(5654):26.
70. Normile D., Vogel G. Infectious diseases. Early indications point to lab infection in new SARS case. Science 2003, 301(5640):1642-1643.
71. Nowotny N., Kolodziejek J. Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels, Oman, 2013. Eurosurveillance 2014, 19(16):20781.
72. Peiris J.S., Lai S.T., Poon L.L., Guan Y., Yam L.Y., Lim W., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003, 361(9366):1319-1325.
73. Poutanen S.M., Low D.E., Henry B., Finkelstein S., Rose D., Green K., et al. Identification of severe acute respiratory syndrome in Canada. N. Engl. J. Med. 2003, 348(20):1995-2005.
74. Qin C., Wang J., Wei Q., She M., Marasco W.A., Jiang H., et al. An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus. J. Pathol. 2005, 206(3):251-259.
75. Raj V.S., Mou H., Smits S.L., Dekkers D.H., Muller M.A., Dijkman R., et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013, 495(7440):251-254.
76. Raj V.S., Smits S.L., Provacia L.B., van den Brand J.M., Wiersma L., Ouwendijk W.J., et al. Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus. J. Virol. 2014, 88(3):1834-1838.
77. Reusken C.B., Haagmans B.L., Muller M.A., Gutierrez C., Godeke G.J., Meyer B., et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect. Dis. 2013, 13(10):859-866.
78. Reusken C.B., Ababneh M., Raj V.S., Meyer B., Eljarah A., Abutarbush S., et al. Middle East respiratory syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. Eurosurveillance 2013, 18(50):20662.
79. Roberts A., Subbarao K. Animal models for SARS. Adv. Exp. Med. Biol. 2006, 581:463-471.
80. Roberts A., Vogel L., Guarner J., Hayes N., Murphy B., Zaki S., et al. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J. Virol. 2005, 79(1):503-511.
81. Roberts A., Paddock C., Vogel L., Butler E., Zaki S., Subbarao K. Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans. J. Virol. 2005, 79(9):5833-5838.
82. Roberts A., Thomas W.D., Guarner J., Lamirande E.W., Babcock G.J., Greenough T.C., et al. Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters. J. Infect. Dis. 2006, 193(5):685-692.
83. Roberts A., Deming D., Paddock C.D., Cheng A., Yount B., Vogel L., et al. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog. 2007, 3(1):e5.
84. Roberts A., Lamirande E.W., Vogel L., Jackson J.P., Paddock C.D., Guarner J., et al. Animal models and vaccines for SARS-CoV infection. Virus Res. 2008, 133(1):20-32.
85. Rockx B., Feldmann F., Brining D., Gardner D., LaCasse R., Kercher L., et al. Comparative pathogenesis of three human and zoonotic SARS-CoV strains in cynomolgus macaques. PloS One 2011, 6(4):e18558.
86. Rowe T., Gao G., Hogan R.J., Crystal R.G., Voss T.G., Grant R.L., et al. Macaque model for severe acute respiratory syndrome. J. Virol. 2004, 78(20):11401-11404.
87. Ruan Y.J., Wei C.L., Ee A.L., Vega V.B., Thoreau H., Su S.T., et al. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet 2003, 361(9371):1779-1785.
88. Severe acute respiratory syndrome (SARS), 2003. Releve epidemiologique hebdomadaire/Section d[U+05F3]hygiene du Secretariat de la Societe des Nations=Weekly epidemiological record/Health Section of the Secretariat of the League of Nations 78 (12), 81-83.
89. Subbarao K., McAuliffe J., Vogel L., Fahle G., Fischer S., Tatti K., et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J. Virol. 2004, 78(7):3572-3577.
90. Tsang K.W., Ho P.L., Ooi G.C., Yee W.K., Wang T., Chan-Yeung M., et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 2003, 348(20):1977-1985.
91. Tseng C.T., Huang C., Newman P., Wang N., Narayanan K., Watts D.M., et al. Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human angiotensin-converting enzyme 2 virus receptor. J. Virol. 2007, 81(3):1162-1173.
92. ter Meulen J., Bakker A.B., van den Brink E.N., Weverling G.J., Martina B.E., Haagmans B.L., et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 2004, 363(9427):2139-2141.
93. van Boheemen S., de Graaf M., Lauber C., Bestebroer T.M., Raj V.S., Zaki A.M., et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio 2012, 3(6). e00473-12.
94. van den Brand J.M., Haagmans B.L., Leijten L., van Riel D., Martina B.E., Osterhaus A.D., et al. Pathology of experimental SARS coronavirus infection in cats and ferrets. Vet. Pathol. 2008, 45(4):551-562.
95. van Doremalen N., Miazgowicz K.L., Milne-Price S., Bushmaker T., Robertson S., Scott D., et al. Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4. J. Virol. 2014, 88(16):9220-9232.
96. WHO, 2003a. Cumulative Number of Reported Probable Cases of SARS [updated July 11, 2003]. Available from: . http://www.who.int/entity/csr/sars/country/2003_07_11/en/index.html.
97. WHO, 2003b. World Health Organization issues emergency travel advisory. Available from: . http://www.who.int/csr/sars/archive/2003_03_15/en/.
98. WHO, 2014. Middle East respiratory syndrome coronavirus (MERS-CoV) [updated May 9, 2014; cited December 11, 2014]. Available from: . http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_Update_09_May_2014.pdf?ua=1.
99. Wang N., Shi X., Jiang L., Zhang S., Wang D., Tong P., et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 2013, 23(8):986-993.
100. Watts D.M., Peters C.J., Newman P., Wang N., Yoshikawa N., Tseng C.K., et al. Evaluation of cotton rats as a model for severe acute respiratory syndrome. Vector Borne Zoonotic Dis. 2008, 8(3):339-344.
101. Weingartl H., Czub M., Czub S., Neufeld J., Marszal P., Gren J., et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J. Virol. 2004, 78(22):12672-12676.
102. Wentworth D.E., Gillim-Ross L., Espina N., Bernard K.A. Mice susceptible to SARS coronavirus. Emerg. Infect. Dis. 2004, 10(7):1293-1296.
103. Wu D., Tu C., Xin C., Xuan H., Meng Q., Liu Y., et al. Civets are equally susceptible to experimental infection by two different severe acute respiratory syndrome coronavirus isolates. J. Virol. 2005, 79(4):2620-2625.
104. Wu K., Chen L., Peng G., Zhou W., Pennell C.A., Mansky L.M., et al. A virus-binding hot spot on human angiotensin-converting enzyme 2 is critical for binding of two different coronaviruses. J. Virol. 2011, 85(11):5331-5337.
105. Wu K., Peng G., Wilken M., Geraghty R.J., Li F. Mechanisms of host receptor adaptation by severe acute respiratory syndrome coronavirus. J. Biol. Chem. 2012, 287(12):8904-8911.
106. Yang X.H., Deng W., Tong Z., Liu Y.X., Zhang L.F., Zhu H., et al. Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection. Comp. Med. 2007, 57(5):450-459.
107. Yang Z.Y., Kong W.P., Huang Y., Roberts A., Murphy B.R., Subbarao K., et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004, 428(6982):561-564.
108. Yao Y., Bao L., Deng W., Xu L., Li F., Lv Q., et al. An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus. J. Infect. Dis. 2014, 209(2):236-242.
109. Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 2012, 367(19):1814-1820.
110. Zhang N., Jiang S., Du L. Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Revi. Vaccines 2014, 13(6):761-774.
111. Zhang N., et al. Receptor-binding domain-based subunit vaccines against MERS-CoV. Virus Res. 2014, 10.1016/j.virusres.2014.11.013.
112. Zhao J., Li K., Wohlford-Lenane C., Agnihothram S.S., Fett C., Zhao J., et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc. Natl. Acad. Sci. USA 2014, 111(13):4970-4975.
113. Zhong N.S., Zheng B.J., Li Y.M., Poon, Xie Z.H., Chan K.H., et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People[U+05F3]s Republic of China, in February, 2003. Lancet 2003, 362(9393):1353-1358.
114. Zornetzer G.A., Frieman M.B., Rosenzweig E., Korth M.J., Page C., Baric R.S., et al. Transcriptomic analysis reveals a mechanism for a prefibrotic phenotype in STAT1 knockout mice during severe acute respiratory syndrome coronavirus infection. J. Virol. 2010, 84(21):11297-11309.